Beijing Konruns PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Beijing Konruns PharmaceuticalLtd's earnings have been declining at an average annual rate of -20.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 2.2% per year. Beijing Konruns PharmaceuticalLtd's return on equity is 5.9%, and it has net margins of 17.4%.
Key information
-20.4%
Earnings growth rate
-20.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -2.2% |
| Return on equity | 5.9% |
| Net Margin | 17.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Beijing Konruns PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 954 | 166 | 604 | 85 |
| 31 Dec 23 | 920 | 150 | 583 | 95 |
| 30 Sep 23 | 999 | 146 | 568 | 99 |
| 30 Jun 23 | 946 | 112 | 560 | 91 |
| 31 Mar 23 | 876 | 81 | 532 | 91 |
| 31 Dec 22 | 867 | 101 | 528 | 87 |
| 30 Sep 22 | 801 | 114 | 528 | 91 |
| 30 Jun 22 | 726 | 130 | 453 | 84 |
| 31 Mar 22 | 755 | 130 | 460 | 103 |
| 31 Dec 21 | 810 | 148 | 481 | 102 |
| 30 Sep 21 | 855 | 179 | 505 | 98 |
| 30 Jun 21 | 916 | 180 | 568 | 110 |
| 31 Mar 21 | 949 | 216 | 603 | 96 |
| 31 Dec 20 | 809 | 183 | 533 | 93 |
| 30 Sep 20 | 855 | 204 | 550 | 89 |
| 30 Jun 20 | 870 | 220 | 562 | 94 |
| 31 Mar 20 | 944 | 249 | 587 | 104 |
| 31 Dec 19 | 1,066 | 266 | 678 | 109 |
| 30 Sep 19 | 1,038 | 311 | 684 | 131 |
| 30 Jun 19 | 1,029 | 313 | 669 | 116 |
| 31 Mar 19 | 982 | 273 | 669 | 91 |
| 31 Dec 18 | 973 | 264 | 657 | 80 |
| 30 Sep 18 | 897 | 215 | 587 | 40 |
| 31 Dec 17 | 591 | 479 | 322 | 32 |
| 31 Dec 16 | 346 | 192 | 102 | 38 |
| 31 Dec 15 | 436 | 195 | 185 | 39 |
Quality Earnings: 603590 has high quality earnings.
Growing Profit Margin: 603590's current net profit margins (17.4%) are higher than last year (9.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603590's earnings have declined by 20.4% per year over the past 5 years.
Accelerating Growth: 603590's earnings growth over the past year (106.2%) exceeds its 5-year average (-20.4% per year).
Earnings vs Industry: 603590 earnings growth over the past year (106.2%) exceeded the Pharmaceuticals industry -1.5%.
Return on Equity
High ROE: 603590's Return on Equity (5.9%) is considered low.